Antitumor therapy based on the use of an immune modulator, arginine butyrate and interferon.
The analysis of the likely physiological role of interferon during pregnancy and antitumor protection can be employed in developing a new strategy in antitumor therapy. Indeed, pretreatment of the patients with a potent immune stimulation compensates to some extent interferon's immune repressive effects. Through the modulation of the cytoskeleton, interferon enhances macrophage activity. Moreover, butyrate by its own effect on the malignant phenotype increases interferon sensitivity in a number of malignant cells. All of these substances should be used at the lowest possible concentration delivered as closely as possible to the target area.
D000653:Amniotic Fluid / Q000032:analysis; D000818:Animals; D001120:Arginine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002087:Butyrates; D003599:Cytoskeleton / Q000187:drug effects; D005109:Extracellular Matrix / Q000187:drug effects; D005260:Female; D006801:Humans; D007107:Immune System / Q000187:drug effects; D007372:Interferons / Q000008:administration & dosage* / Q000494:pharmacology; D051379:Mice; D008806:Mice, Inbred AKR; D009369:Neoplasms / Q000628:therapy*; D011247:Pregnancy; D011425:Propionibacterium acnes / Q000276:immunology; D051381:Rats; D012510:Sarcoma 180 / Q000628:therapy
D002087:Butyrates; D007372:Interferons; D001120:Arginine; C033018:arginine butyrate